Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy
Cytokine-induced killer (CIK) cells are demonstrated to possess potent cytolytic effect against ovarian cancer cells in vitro and in vivo. However, the clinical efficacy of maintenance therapy of CIK cells in patients with epithelial ovarian cancer (EOC) after first-line treatment remains unclear. T...
Main Authors: | Yun Zhou, Chang-long Chen, Sen-wei Jiang, Yanling Feng, Linjing Yuan, Ping Chen, Lan Zhang, Shuting Huang, Jundong Li, Jian-Chuan Xia, Min Zheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-02-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2018.1528411 |
Similar Items
-
Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer
by: Soo Young Jeong, et al.
Published: (2019-12-01) -
Gut Microbiota Dynamics during Chemotherapy in Epithelial Ovarian Cancer Patients Are Related to Therapeutic Outcome
by: Federica D’Amico, et al.
Published: (2021-08-01) -
Remission-Stage Ovarian Cancer Cell Vaccine with Cowpea Mosaic Virus Adjuvant Prevents Tumor Growth
by: Courtney T. Stump, et al.
Published: (2021-02-01) -
Melatonin and Fertoprotective Adjuvants: Prevention against Premature Ovarian Failure during Chemotherapy
by: Hoon Jang, et al.
Published: (2017-06-01) -
PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer
by: Zi-Qi Zhou, et al.
Published: (2019-08-01)